OKYO Stock Forecast & Price Target

OKYO Pharma Ltd has demonstrated significant progress in the clinical development of urcosimod, particularly in its potential to address chronic pain, with promising clinical results indicating that 67% of patients in the 0.05% urcosimod group achieved more than 50% improvement in pain levels compared to only 33% in the placebo cohort. Notably, the therapy exhibited a marked reduction in pain scores as early as Week 4, suggesting rapid efficacy in pain management. These developments underscore a strong potential for positive outcomes in the company's therapeutic offerings, reinforcing a favorable outlook on its future financial performance.

OKYO Pharma Ltd reported a net loss of $4.7 million for the fiscal year 2025, amounting to ($0.12) per share, indicating a negative financial performance that may raise concerns among investors. The analysis suggests significant risks associated with the development of the investigational product urcosimod, including potential failures in clinical trials and challenges in securing regulatory approval in the U.S. Additionally, there are concerns regarding market size, penetration rates, and competition, which could jeopardize the commercial success of urcosimod, further contributing to the negative outlook on the company's stock.